This Article Full Text Full Text (PDF) Publisher's Note Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tolcher, A. W. Articles by Cohen, R. B. Search for Related Content PubMed PubMed Citation Articles by Tolcher, A. W. Articles by Cohen, R. B. Related Articles Related Correspondence Social Bookmarking                            What's this?

Phase I Pharmacokinetic and Biologic Correlative Study of Mapatumumab, a Fully Human Monoclonal Antibody With Agonist Activity to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Receptor-1

Anthony W. Tolcher, Monica Mita, Neal J. Meropol, Margaret von Mehren, Amita Patnaik, Kristin Padavic, Monique Hill, Theresa Mays, Therese McCoy, Norma Lynn Fox, Wendy Halpern, Alfred Corey, Roger B. Cohen

From the Institute for Drug Development, Cancer Therapy and Research Center; The University of Texas Health Science Center at San Antonio, San Antonio, TX; Fox Chase Cancer Center, Philadelphia, PA; and Human Genome Sciences, Rockville, MD

Address reprint requests to Anthony W. Tolcher MD, FRCP (C), Institute for Drug Development, Cancer Therapy and Research Center, 7979 Wurzbach, Suite 414, San Antonio, TX 78229; e-mail: atolcher{at}idd.org

Purpose To assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of mapatumumab (HGS-ETR1, TRM-1), a fully human agonist monoclonal antibody directed to the tumor necrosis factor–related apoptosis-inducing ligand receptor-1 (TRAIL-R1).

Patients and Methods Patients with advanced solid malignancies were treated with escalating doses of mapatumumab intravenously (IV) administered over 30 to 120 minutes, initially as a single dose and then repetitively. Plasma mapatumumab concentrations were measured and serum was assayed to detect human antimapatumumab antibody formation. Archival tumor specimens were collected to detect the presence of TRAIL-R1 by immunohistochemistry.

Results Forty-nine patients received 158 courses at doses ranging from 0.01 to 10 mg/kg IV. Initially, patients received mapatumumab as a single dose, then every 28 days repetitively, and then 10 mg/kg every 14 days. Mild (grade 1 or 2) fatigue, fever, and myalgia were the most frequently reported nonhematologic adverse events related to mapatumumab, whereas hematologic toxicity was not clinically significant. The mean (± standard deviation) clearance and terminal elimination half-life values for mapatumumab at 10 mg/kg every 14 days were 3.7 mL/d/kg (± 1.5 mL/d/kg) and 18.8 days (± 10.1 days), respectively. TRAIL-R1 was documented in 68% of patients' tumors assayed. Nineteen patients had stable disease, with two lasting 9 months.

Conclusion Mapatumumab can be administered safely and feasibly at 10 mg/kg IV every 14 days. The absence of severe toxicities and the attainment of plasma mapatumumab concentrations that are active in preclinical models warrant further disease-directed studies of this agent alone and in combination with chemotherapy in a broad array of tumors.

Supported by Human Genome Sciences Inc.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

Related Correspondence

• Barriers to Effective TRAIL-Targeted Therapy of Malignancy
  Martin J.S. Dyer, Marion MacFarlane, and Gerald M. Cohen
  JCO 2007 25: 4505-4506 [Full Text]

This article has been cited by other articles:

				G Kallifatidis, V Rausch, B Baumann, A Apel, B M Beckermann, A Groth, J Mattern, Z Li, A Kolb, G Moldenhauer, et al. Sulforaphane targets pancreatic tumour-initiating cells by NF-{kappa}B-induced antiapoptotic signalling Gut, July 1, 2009; 58(7): 949 - 963. [Abstract] [Full Text] [PDF]

				S R Mucha, A Rizzani, A L Gerbes, P Camaj, W E Thasler, C J Bruns, S T Eichhorst, E Gallmeier, F T Kolligs, B Goke, et al. JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand Gut, May 1, 2009; 58(5): 688 - 698. [Abstract] [Full Text] [PDF]

				A. Labrinidis, P. Diamond, S. Martin, S. Hay, V. Liapis, I. Zinonos, N. A. Sims, G. J. Atkins, C. Vincent, V. Ponomarev, et al. Apo2L/TRAIL Inhibits Tumor Growth and Bone Destruction in a Murine Model of Multiple Myeloma Clin. Cancer Res., March 15, 2009; 15(6): 1998 - 2009. [Abstract] [Full Text] [PDF]

				X.-X. Wu and Y. Kakehi Enhancement of Lexatumumab-Induced Apoptosis in Human Solid Cancer Cells by Cisplatin in Caspase-Dependent Manner Clin. Cancer Res., March 15, 2009; 15(6): 2039 - 2047. [Abstract] [Full Text] [PDF]

				W. W. Ma and A. A. Adjei Novel Agents on the Horizon for Cancer Therapy CA Cancer J Clin, March 1, 2009; 59(2): 111 - 137. [Abstract] [Full Text] [PDF]

				M. Fakler, S. Loeder, M. Vogler, K. Schneider, I. Jeremias, K.-M. Debatin, and S. Fulda Small molecule XIAP inhibitors cooperate with TRAIL to induce apoptosis in childhood acute leukemia cells and overcome Bcl-2-mediated resistance Blood, February 19, 2009; 113(8): 1710 - 1722. [Abstract] [Full Text] [PDF]

				E. G.E. de Vries and S. de Jong Exploiting the Apoptotic Route for Cancer Treatment: A Single Hit Will Rarely Result in a Home Run J. Clin. Oncol., November 10, 2008; 26(32): 5151 - 5153. [Full Text] [PDF]

				A. J. Frew, R. K. Lindemann, B. P. Martin, C. J. P. Clarke, J. Sharkey, D. A. Anthony, K.-M. Banks, N. M. Haynes, P. Gangatirkar, K. Stanley, et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist PNAS, August 12, 2008; 105(32): 11317 - 11322. [Abstract] [Full Text] [PDF]

				K. Takeda, Y. Kojima, K. Ikejima, K. Harada, S. Yamashina, K. Okumura, T. Aoyama, S. Frese, H. Ikeda, N. M. Haynes, et al. Death receptor 5 mediated-apoptosis contributes to cholestatic liver disease PNAS, August 5, 2008; 105(31): 10895 - 10900. [Abstract] [Full Text] [PDF]

				S. J. Hotte, H. W. Hirte, E. X. Chen, L. L. Siu, L. H. Le, A. Corey, A. Iacobucci, M. MacLean, L. Lo, N. L. Fox, et al. A Phase 1 Study of Mapatumumab (Fully Human Monoclonal Antibody to TRAIL-R1) in Patients with Advanced Solid Malignancies Clin. Cancer Res., June 1, 2008; 14(11): 3450 - 3455. [Abstract] [Full Text] [PDF]

				A. Ocana and A. Pandiella Identifying Breast Cancer Druggable Oncogenic Alterations: Lessons Learned and Future Targeted Options Clin. Cancer Res., February 15, 2008; 14(4): 961 - 970. [Abstract] [Full Text] [PDF]

				D. S. Ziegler, A. L. Kung, and M. W. Kieran Anti-Apoptosis Mechanisms in Malignant Gliomas J. Clin. Oncol., January 20, 2008; 26(3): 493 - 500. [Abstract] [Full Text] [PDF]

				E. J. Benz Jr., D. G. Nathan, R. K. Amaravadi, and N. N. Danial Targeting the Cell Death-Survival Equation Clin. Cancer Res., December 15, 2007; 13(24): 7250 - 7253. [Full Text] [PDF]

				R. K. Amaravadi and C. B. Thompson The Roles of Therapy-Induced Autophagy and Necrosis in Cancer Treatment Clin. Cancer Res., December 15, 2007; 13(24): 7271 - 7279. [Abstract] [Full Text] [PDF]

				M. J.S. Dyer, M. MacFarlane, and G. M. Cohen Barriers to Effective TRAIL-Targeted Therapy of Malignancy J. Clin. Oncol., October 1, 2007; 25(28): 4505 - 4506. [Full Text] [PDF]

				T. F. Gajewski On the TRAIL Toward Death Receptor-Based Cancer Therapeutics J. Clin. Oncol., April 10, 2007; 25(11): 1305 - 1307. [Full Text] [PDF]